Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Oncology Report

• Publication date

  2006-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/OR.16.6.1381PMID 17089065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gemcitabine in bladder cancer

  2007cited by this paper
• Sequential administration of cisplatin (c), gemcitabine (g) and docetaxel (d), as first-line treatment in patients with advanced transitional cell carcinoma (TCC) of the urothelial tract: A multicenter phase II study.

  2006cited by this paper
• Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.

  2005cited by this paper
• Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium

  2005cited by this paper
• Taxol and taxotere in bladder cancer: in vitro activity and urine stability

  2004cited by this paper
• Recent advances in bladder cancer diagnostics.

  2004cited by this paper
• New drugs and new approaches in metastatic bladder cancer.

  2003cited by this paper
• Gemcitabine in transitional cell carcinoma of the urothelium

  2003cited by this paper
• Overview of gemcitabine triplets in metastatic bladder cancer.

  2003cited by this paper
• Gemcitabine in transitional cell carcinoma of the urothelium

  2003cited by this paper
• Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.

  2002cited by this paper
• Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.

  2002cited by this paper
• Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer.

  2002cited by this paper
• Current and future perspectives in advanced bladder cancer: is there a new standard?

  2002cited by this paper
• Familial aggregation of urothelial cell carcinoma

  2002cited by this paper
• Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine

  2002cited by this paper
• Bladder cancer.

  2002cited by this paper
• Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.

  2001cited by this paper
• Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study.

  2000cited by this paper
• Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.

  2000cited by this paper
• Gemcitabine in bladder cancer.

  2000cited by this paper
• Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.

  2000cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group.

  1999cited by this paper
• Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy.

  1999cited by this paper
• A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.

  1998cited by this paper
• Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.

  1998cited by this paper
• Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.

  1998cited by this paper
• Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

  1997cited by this paper
• Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

  1997cited by this paper
• Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.

  1997cited by this paper
• Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.

  1997cited by this paper
• Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.

  1996cited by this paper
• Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review

  1996cited by this paper
• Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.

  1996cited by this paper
• Interaction between cisplatin and gemcitabine in vitro and in vivo.

  1995cited by this paper
• Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study.

  1994cited by this paper
• Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

  1994cited by this paper
• The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.

  1993cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

  1990cited by this paper
• Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

  1989cited by this paper
• Chemotherapy of urothelial tract tumors

  1987cited by this paper
• Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.

  1985cited by this paper
• Cancer: Principles and Practice of Oncology

  1983cited by this paper
• A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group a study

  1983cited by this paper
• [Systemic chemotherapy of bladder cancer].

  1982cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison.

  1978cited by this paper
• [Cancer of the bladder].

  1951cited by this paper

• The Role of Chemotherapy in Locally Advanced and Metastatic Bladder Cancer

  2021cites this paper
• Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma.

  2021cites this paper
• Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma

  2016cites this paper
• The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.

  2016cites this paper
• Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report

  2015cites this paper
• Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.

  2014cites this paper
• Relationship between 6‐ and 9‐month progression‐free survival and overall survival in patients with metastatic urothelial cancer treated with first‐line cisplatin‐based chemotherapy

  2013cites this paper
• Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin‐based chemotherapy

  2013cites this paper
• The impact of gender on outcomes in patients with metastatic urothelial carcinoma.

  2013cites this paper
• Superior vena cava syndrome due to metastasis from urothelial cancer: A case report and literature review

  2013cites this paper
• Quimioprofilaxis en la recidiva tumoral vesical

  2012cites this paper
• UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity.

  2011cites this paper
• Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma

  2011cites this paper
• Mitigating cisplatin resistance in ovarian cancer.

  2011cites this paper
• ASCO 2007: “Translating Research into Practice”. Report from the 34th annual meeting of the American Society of Clinical Oncology

  2011cites this paper
• Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of combination chemotherapy in bladder cancer cells.

  2009cites this paper
• Uro-Onkologie – Update 2009

  2009cites this paper
• Intravesical Treatments of Bladder Cancer: Review

  2008cites this paper
• [Gemcitabine and pemetrexed in genito-urinary tumors treatment].

  2007cites this paper
• New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder

  2007cites this paper